Alector, Inc.
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial forā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.25
Price-8.54%
-$0.21
1Y
Price
Market Cap
$227.727m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$88.339m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$123.441m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$1.27
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$94.610m
$408.303m
Assets$313.693m
Liabilities$41.048m
DebtDebt to Assets
10.1%
-0.3x
Debt to EBITDAFree Cash Flow
-$230.084m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company